Comprehensive genomic profiling service for haematological malignancies and sarcomas; to guide diagnosis, prognosis and treatment selection and personalise patients' treatment plans.1- 3
This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.
This site is produced by Roche as a partner of Roche Foundation Medicine.
Experience how FoundationOne Heme can guide diagnosis, prognosis and treatment selection, and help personalise your patients' treatment plans.1- 3
FoundationOne Heme samples can be shipped to our Penzberg (Germany) or Cambridge (US) laboratories for patients in the EU or the rest of the world, respectively, enabling more patients to benefit from comprehensive genomic profiling with FoundationOne Heme.†
Acceptable specimen types:
1. For haematological malignancies, multiple specimen types are acceptable; FoundationOne Heme has been validated with blood, bone marrow aspirate and FFPE tissue samples1,39
2. For sarcoma, please use FFPE tissue samples39
3. Our dedicated c lient service team offers information and support to ensure specimen requirements for analysis are met
"Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.
†Peripheral blood and bone marrow aspirate must be received the day after collection for optimal analysis as sensitivity of detection may degrade with t ime. Samples arriving later will result in a Qualified Report. FFPE block or slides are also accepted.
AML, acute myeloid leukaemia. ALL, acute lymphoblastic leukaemia. CLL, chronic lymphocytic leukaemia. GIST, gastrointestinal stromal tumours. DLBCL, diffuse large 8-cell lymphoma. FFPE, formalin-fixed paraffin-embedded. MOS, myetodysplastic syndrome. MM, multiple myeloma. MPN, myeloproliferative neoplasms. MSI, microsatellite instability. RMS, rhabdomyosarcoma. TKI, tyrosine kinase inhibitor. TMB, tumour mutational burden.